http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2198058-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44df766f7fca9d1c4f11e8e597b09ef1 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57446 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
filingDate | 2008-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e979c22cd69029a2c9e4df23233623d |
publicationDate | 2010-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-2198058-A2 |
titleOfInvention | Marker for the diagnosis of cancer |
abstract | The invention relates to the use of phosphoglycerate-kinase 1 (PGK1), or fragments thereof, as a diagnostic marker m for the prognosis or diagnosis of peritoneal carcinamatoses and/or metastasizing primary tumours. The invention also relates to the use of an active substance that inhibits the activity and/or expression of phosphoglycerate-kinase 1 (PGK1), combined with an active substance that inhibits the activity and/or expression of beta-catenin, CXCR4 and/or CXCL12, for producing a medicament for the treatment and/or prevention of peritoneal carcinamatoses and/or metastasizing primary tumours. The invention further relates to pharmaceutical compositions comprising an active substance that inhibits the activity and/or expression of phosphoglycerate-kinase 1 (PGK1), and optionally, at least one pharmaceutically acceptable carrier, and pharmaceutical compositions comprising an active substance that inhibits the activity and/or the expression of phosphoglycerate-kinase 1 (PGK1), and at least one active substance that inhibits the activity and/or expression of beta-catenin, CXCR4 and/or CXCL12, and optionally, at least one pharmaceutically acceptable carrier. |
priorityDate | 2007-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 125.